Cambridge-based techbio drug development company Closed Loop Medicine has appointed Luba Greenwood as its chair.

Greenwood is an executive and investor with more than 20 years’ experience in healthcare and tech. She has led over $10 billion in deals and investment over multiple therapeutic areas, in companies across the life sciences, medical devices, diagnostics and tech sectors, including co-founding biotech and digital companies in the immunotherapy, women’s health, artificial intelligence/machine learning and microbiome sector.

Greenwood is the managing partner of Binney Street Capital, a venture fund she founded at the Dana-Farber Cancer Institute and was previously chief executive and chair of Kojin Therapeutics, a company developing small-molecule therapeutics for a wide range of diseases. She has previously held leadership roles at Google Life Sciences (Verily) and as vice-president of global business development and M&A at Roche. She is a former lawyer with an understanding of corporate governance and regulatory, policy, and intellectual property across the pharmaceutical, biotechnology and technology industries.

She has sat on the boards and acted as an advisor to numerous private and publicly-traded companies, including Abcam and the non-profit Massachusetts Biotechnology Council.

Greenwood said: “By catalysing the development of more precise therapeutics across vast disease areas, Closed Loop’s platform has the potential to not only improve drug safety and efficacy, but transform the way healthcare is delivered. The work I do, and have been doing, has been driven by my dedication to bringing innovative products to market and ultimately to patients. I’m excited to be a part of the company’s pioneering journey for better medicines, alongside a very impressive board of directors, to bring precision medicines to all patients in need.”

Closed Loop Medicine’s co-founder and chief executive Hakim Yadi commented: “[Greenwood’s] impressive background and expertise in healthcare and tech, particularly as it pertains to the US market, will be instrumental in bolstering the company’s strategic growth. With her strong track-record of building world-class teams and companies, we are well-positioned for the commercialisation of our products and the expansion of our partnerships.”